|
| Status |
Public on Jan 21, 2014 |
| Title |
Expression Data from transNOAH breast cancer trial |
| Organism |
Homo sapiens |
| Experiment type |
Expression profiling by array
|
| Summary |
These data can be used for evaluation of the clinical utility of the research-based PAM50 subtype predictor in predicting pathological complete response (pCR) and event-free survival (EFS) in women enrolled in the NeOAdjuvant Herceptin (NOAH) trial.
The NeOAdjuvant Herceptin [NOAH] trial demonstrated that trastuzumab significantly improves pCR rates and 3-year event-free survival (EFS) in combination with neoadjuvant chemotherapy compared with neoadjuvant chemotherapy alone in patients with HER2+ breast cancer.
|
| |
|
| Overall design |
Gene expression profiling was performed using RNA from formalin-fixed paraffin-embedded core biopsies from 114 pre-treated patients with HER2-positive (HER2+) tumors randomized to receive neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF), or the same regimen in combination with trastuzumab for 1 year. A control cohort of 42 patients with HER2-negative tumors treated with AT-CMF was also included.
This dataset represents 156 patients who had provided the samples at baseline (pre-treatment).
|
| |
|
| Contributor(s) |
Belousov A, Prat A |
| Citation(s) |
24443618 |
| |
| Submission date |
Sep 17, 2013 |
| Last update date |
Jun 06, 2022 |
| Contact name |
Anton Belousov |
| Organization name |
Roche
|
| Department |
NCS-TTB
|
| Lab |
TTB Biostatistics
|
| Street address |
Nonnenwald 2
|
| City |
Penzberg |
| ZIP/Postal code |
82377 |
| Country |
Germany |
| |
|
| Platforms (1) |
| GPL570 |
[HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array |
|
| Samples (156)
|
|
| Relations |
| BioProject |
PRJNA219444 |
Less...
More...